程雪,方泓,吴银根

• 1:上海中医药大学附属龙华医院

摘要(Abstract)：

目的观察肺痹方对博来霉素诱导的肺纤维化小鼠抗氧化作用,并探讨其机制。方法将60只C57BL/6雄性小鼠随机分为空白对照组、模型组、吡非尼酮组[51.43 mg/(kg·d)]、肺痹方低剂量组[6.43 g/(kg·d)]、肺痹方中剂量组[12.86 g/(kg·d)]、肺痹方高剂量组[25.72g/(kg·d)],每组10只。除空白对照组外,其余各组按7.5 mg/(kg·d)腹腔注射博来霉素,空白对照组腹腔注射等量的生理盐水,连续注射10 d。造模后第2天灌胃给药,空白对照组和模型组给予等量生理盐水灌胃,给药时间为4周。每周称取各组小鼠的体质量,监测小鼠的一般情况。实验结束后,计算肺纤维化小鼠的肺系数,取右肺中叶测定各组小鼠肺组织均浆中的羟脯氨酸(HYP)、超氧化物歧化酶(SOD)、还原谷胱甘肽(GSH)、丙二醛(MDA)的含量。取小鼠左肺,用于HE染色和Masson染色,观察其组织病理改变。结果与其他各组相比,模型组肺泡炎和肺纤维化程度明显增加,肺系数和肺组织HYP、MDA的含量明显升高,肺组织SOD、GSH含量明显降低(P<0.05或P<0.01);与模型组相比,各给药组可明显改善肺纤维化小鼠肺泡炎及肺纤维化程度,降低肺系数、肺组织中HYP、MDA的含量(P<0.05或P<0.01),升高肺组织中SOD、GSH的活性。结论肺痹方具有良好的抗炎、抗氧化作用,对博来霉素诱导肺纤维化小鼠具有一定治疗作用。

关键词(KeyWords)： 肺纤维化小鼠;肺痹方;抗氧化

Abstract:

Keywords:

基金项目(Foundation): 国家中医药管理局全国名老中医药专家传承工作室建设项目(LH02.07.005)

作者(Author): 程雪,方泓,吴银根

参考文献(References)：

• [1]Raghu G,Collard HR,Egan JJ,et al.An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J].Am J Respir Crit Care Med,183(2011):788-824.
• [2]Fraser E,Hoyles RK.Therapeutic advances in idiopathic pulmonary fibrosis[J].Clinical Medicine,16(2016):42-51.
• [3]Rosenbloom J,Mendoza FA,Jimenez SA.Strategies for antifibrotic therapies[J].Biochim Biophys Acta,2013,1832(7):1088-1103.
• [4]苏垠旭,龚婕宁.从叶天士“初病在经,久病入络”理论论治肺纤维化[J].世界科学技术-中医药现代化,2015,17(6):1280-1284.
• [5]吴银根,唐斌擎.吴银根肺系疾病中医诊疗思路与经验[M].上海:上海科学技术出版社,2016:198.
• [6]Maeda A,Hiyama K,Yamakido H,et al.Increased expression of platelet-derived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycininduced pulmonary fibrosis in mice[J].Chest,1996,109:780-786.
• [7]章元沛.药理学实验[M].北京:人民卫生出版社,1996:238.
• [8]Szapiel SV,Elson NA,Fulmer JD,et al.Bleomycin-induced interstitial pulmonary disease in the nude,athymic mouse[J].Am Rey Respir Dis,1979,120:893-899.
• [9]Kang YP,Lee JM.Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis[J].J Proteome Res.2016,15(5):1717-1724.
• [10]Costabel U.The changing treatment landscape in idiopathic pulmonary fibrosis[J].Eur Respir Rev,2015,24(135):65-68.
• [11]Henn V,Slupsky JR,Grafe M,et al.CD40 ligand on activated platelets triggers and inflammatory reaction of endothelial cells[J].Natrue,1998,391(6667):591-594.
• [12]Meyer C,Nathan SD.Idiopathic pulmonary fibrosis:a comprehensive clinical guide[J].Totowa,NJ,Humana Press,2013.
• [13]Cottin V,Maher T.Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis[J].Eur Respir Rev,2015,24(135):58-64.
• [14]Valeyre D,Albera C,Bradford WZ,et al.Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis[J].Respirology,2014:19:740-748.
• [15]Costabel U,Bendstrup E,Cottin V,et al.Pirfenidone in idiopathic pulmonary fibrosis:expert panel discussion on the management of drug-related adverse events[J].Adv Ther,2014,31:375-391.
• [16]Weidner N.Intratumor microvessel density as a prognostic factor in cancer[J].Am J Pathol,1995,147(1):9-19.
• [17]张天嵩,吴银根.通补肺络法治疗肺纤维化理论探讨[J].中医杂志,2002,43(11):808-810.
• [18]魏详燕,王国娟,王桦影,等.女贞子药理作用研究进展[J].上海中医药杂志,2017,51(8):106-108.